Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Immupharma (IMM)

Price 3.90p on 14-02-2025 at 17:30:00
Change 0.21p 5.53%
Buy 4.12p
Sell 3.90p
Buy / Sell IMM Shares
Add to Watchlist
Add to Portfolio
Add to Quickpicks
Last Trade: Unknown 274,863.00 at 4.00p
Day's Volume: 5,796,821
Last Close: 4.01p
Open: 3.80p
ISIN: GB0033711010
Day's Range 3.80p - 4.08p
52wk Range: 0.83p - 7.26p
Market Capitalisation: £16m
VWAP: 3.885694p
Shares in Issue: 416m

Sector: Medicine and Biotech

Listed In: FTSE AIM All-Share,

Recent Trades History Immupharma (IMM)
Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 274,863 4.00p Ordinary
 15:57:01 - 14-Feb-25
Sell* 2 3.90p Automatic Execution
 16:29:58 - 14-Feb-25
Sell* 100,000 3.915p Ordinary
 16:27:02 - 14-Feb-25
Buy* 7,457 4.09p Ordinary
 16:26:52 - 14-Feb-25
Sell* 16,294 3.915p Ordinary
 16:24:58 - 14-Feb-25
Sell* 80,000 3.9292p Ordinary
 16:21:52 - 14-Feb-25
Sell* 2,000 3.9173p Ordinary
 16:20:11 - 14-Feb-25
Sell* 150,000 4.0302p Ordinary
 16:19:23 - 14-Feb-25
Sell* 625 3.999p Ordinary
 16:18:50 - 14-Feb-25
Sell* 2,316 3.915p Ordinary
 16:12:28 - 14-Feb-25

Share Price History for Immupharma
Time period:
to
Date Open High Low Close Volume

Share News for Immupharma

IN BRIEF: ImmuPharma notes share price surge after novel findings

28th Jan 2025 14:28

ImmuPharma PLC - London-based specialist drug discovery and development company - Notes recent movements in its share price, as it has more than multiplied nearly five times higher in the last month to 6.03p per share, from 1.21p. The stock surged 94% higher in a single day in early January, to 2.33p, after ImmuPharma reported breakthrough findings in its preclinical research programme focused on P140 and the pathogenesis of autoimmune diseases. Read More

IN BRIEF: ImmuPharma shares climb on breakthrough autoimmune findings

9th Jan 2025 11:21

ImmuPharma PLC - London-based specialist drug discovery and development company - Says its preclinical research program focused on P140 and the pathogenesis of autoimmune diseases has yielded data that provides novel insights into autoimmune mechanisms. P140, the firms lead programme, is a unique non-immunosuppressive peptide for the treatment of systemic lupus erythematosus and chronic idiopathic demyelinating polyneuropathy. Adds that the findings, which were discovered by its R&D subsidiary ImmuPharma Biotech, pave the way for better diagnostics, identifying patients most likely to respond to P140 therapy and improved patient monitoring. Says the research marks a "significant step towards personalised medicine in SLE and other autoimmune diseases." Details of the data findings are not being released at this time since they form part of the ongoing expansion of the firms intellectual property portfolio. Read More

AIM WINNERS & LOSERS: ImmuPharma jumps; Impax Asset hit by outflows

9th Jan 2025 09:53

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Thursday. Read More

LONDON MARKET OPEN: Pound slumps to more than one-year low

9th Jan 2025 08:45

(Alliance News) - Stock prices in London made a largely uninspiring start to Thursday, amid a mixed response to Christmas trading statements from high streets, while the pound's descent continued. Read More

ImmuPharma narrows losses in first half as expenses fall

9th Sep 2024 16:46

(Alliance News) - ImmuPharma PLC on Monday expressed optimism about the potential of its pipeline, after narrowing pretax loss in the first half. Read More

FTSE 100 Latest
Value8,732.46
Change-32.26

Login to your account

Forgot Password?

Not Registered